Efficacy and safety of Remdesivir in patients with Covid-19: A review of systematic reviews and meta-analyses
Message:
Article Type:
Review Article (دارای رتبه معتبر)
Abstract:
Background and aims

Remdesivir is an antiviral drug that is widely used in patients with Covid-19. The aim of this study was to review the systematic review and meta-analysis studies of Remdesivir in patients with Covid-19.

Methods

An electronic search was conducted in PubMed, Scopus, Cochrane Library, and Web of Science databases up to December 2021. In addition, other databases were searched. A manual search of studies and other sources was also conducted to find evidence. The tool (Overview Quality Assessment Questionnaire) was used to evaluate the quality of articles.

Results

Seventeen systematic review and meta-analysis studies were included in the study. The results showed that Remdesivir in seven studies reduced the mortality of patients with Covid-19 and in seven other studies had no effect on reducing patient mortality compared to the control group. Other findings of the study also showed that Remdesivir increased clinical improvement, increased clinical recovery, reduced clinical recovery time, and accelerated the discharge time of patients with Covid-19 from the hospital. Side effects were well tolerated in most studies in the Remdesivir group. Adverse events were mild and moderate in most studies in the Remdesivir group.

Conclusion

The findings of the study showed that the mortality rate in patients treated with remedsivir in studies is different, so it is better to use this drug with caution. Adverse events were well tolerated.

Language:
Persian
Published:
Pages:
56 to 66
magiran.com/p2484521  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 990,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
دسترسی سراسری کاربران دانشگاه پیام نور!
اعضای هیئت علمی و دانشجویان دانشگاه پیام نور در سراسر کشور، در صورت ثبت نام با ایمیل دانشگاهی، تا پایان فروردین ماه 1403 به مقالات سایت دسترسی خواهند داشت!
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 50 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!